Ophthalmic Technology Assessment: Thermal Pulsation in the Management of Meibomian Gland Dysfunction and Dry Eye


Tags Cornea
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 12, December 2023


回顧文獻,評估熱脈衝(thermal pulsation)技術在改善瞼板腺功能障礙(MGD)和乾眼症的徵象或症狀方面的療效和安全性,與無治療、常規熱敷療法或lid hygiene相比。結果:所有納入的研究都評估了使用LipiFlow自動化熱脈衝系統(TearScience公司或強生公司)進行的單次12分鐘治療。與無治療相比,經過1至12個月的熱脈衝治療,患者的主觀和客觀的MGD或乾眼症指標均有所改善。在這11個研究中,沒有報告任何嚴重不良事件。結論:根據目前的文獻,單次熱脈衝治療可以安全地改善MGD和乾眼症的主觀或客觀參數。然而,4個8級研究中有4個受到了業內的支持和參與。治療效果能否持久長達幾個月以及成本效益尚不確定。需要進行高質量的獨立研究來評估這種治療的長期效益。

English Abstract

The article reviews the efficacy and safety of thermal pulsation technologies in the management of meibomian gland dysfunction (MGD) and dry eye. The study found that a single 12-minute session of thermal pulsation treatment using the LipiFlow system resulted in improvements in subjective and objective metrics of MGD and dry eye compared to no therapy or conventional warm compress therapy. Four of these studies showed relevant industry conflicts of interest. Two of the 4 level I studies without direct industry participation concluded that thermal pulsation treatment was not significantly different from conventional hygiene or warm compress therapy control treatments (in symptoms in one of the studies and in objective findings in the second study).No serious adverse events were reported in any of the 11 studies reviewed. However, the durability of the treatment beyond several months and cost effectiveness remain uncertain. The article calls for high-quality independent studies to assess the long-term benefits of thermal pulsation therapy.